Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
Metrics and citations
MetadataShow full item record
Author/sMorales-Ponce, Francisco J.; González Pérez, Pablo José; Blasco-Turrión, Sara; Sánchez-Brotons, Juan Antonio; Collado-Moreno, Carmen; Martínez-Romero, Pedro; Martínez-Morentín, Eduardo; Caro-Mateo, Pilar
SourceCardiology Journal 2021, Vol. 28, No. 1, 176–178
Adjunctive medical therapy during primary percutaneous coronary intervention (PPCI) is based on anticoagulation and antiplatelet drugs. Additionally, the glycoprotein IIb/IIIa inhibitor (GPI) abciximab has been shown to reduce infarct size in some clinical trials . However, the role of intracoronary fibrinolysis has not been well established during PPCI. We sought to explore the hypothesis that a locally administered fibrinolytic could be more effective in dissolving coronary thrombus at the macro and microvasculature than adding a third antiplatelet drug in patients already receiving double antiplatelet therapy, and therefore improve myocardial perfusion and left ventricular function.